text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 184475-35-2 | Product Number: G0546

Gefitinib


Purity: >98.0%(T)(HPLC)
Synonyms:
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Product Documents:
1G
32,00 €
1   ≥100 
5G
113,00 €
1   24  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number G0546
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__2H__2__4ClFN__4O__3 = 446.91 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
CAS RN 184475-35-2
Reaxys Registry Number 8949523
PubChem Substance ID 468591928
MDL Number

MFCD04307832

Specifications
Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %
Melting point 194.0 to 198.0 °C
Properties (reference)
Melting Point 196 °C
Maximum Absorption Wavelength 332 nm
Solubility in water Insoluble
Solubility (slightly sol. in) Tetrahydrofuran
GHS
Pictogram Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H361 : Suspected of damaging fertility or the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.
H351 : Suspected of causing cancer.
Precautionary Statements P260 : Do not breathe dust.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
Related Laws:
RTECS# VA0952000
Transport Information:
HS Number 2934999090
Application
Gefitinib: A Potent and Selective Inhibitor of EGFR Tyrosine Kinase

The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation. It is reported that gefitinib (ZD1839) is a potent and selective inhibitor of EGFR tyrosine kinase (EGFRTK). In vitro, gefitinib arrests the cell cycle at G1 phase by inducing intrinsic cyclin-dependent kinase (cdk) inhibitors. Furthermore, gefitinib inhibits vascular endothelial growth factor (VEGF) production in tumor cells through inhibition of EGFR signaling, leading to suppression of angiogenesis. For your reference, [C3647] and [H1606] are key synthetic intermediates of gefitinib. (The product is for research purpose only.)

References


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.